Literature DB >> 11522469

Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.

V Audinot1, A Newman-Tancredi, D Cussac, M J Millan.   

Abstract

The actions of diverse antipsychotics at cloned h5-HT(1B) and h5-HT(1D) receptors were examined employing [3H]-GR125,743 and [35S]-GTPgammaS for determination of affinities and efficacies, respectively. Compared with hD(2) receptors, haloperidol, chlorpromazine and olanzapine showed markedly (>100-fold) lower affinity for h5-HT(1D) and h5-HT(1B) receptors at which they expressed inverse agonist properties. Clozapine, risperidone and ocaperidone likewise behaved as inverse agonists at h5-HT(1B) and h5-HT(1D) receptors but their affinities were only approximately 10-fold lower than at hD(2) receptors. Moreover, ziprasidone, S16924 and ORG5222 interacted at h5-HT(1B) and h5-HT(1D) receptors with affinities similar to hD(2) sites. While S16924 and ORG5222 were inverse agonists at h5-HT(1B) and h5-HT(1D) sites, ziprasidone was an inverse agonist at h5-HT(1D) receptors yet a partial agonist at h5-HT(1B) receptors. These actions of antipsychotics were abolished by the selective, neutral antagonist, S18127. In conclusion, with the exception of ziprasidone, all antipsychotics were inverse agonists at h5-HT(1B) and h5-HT(1D) receptors, although they differed markedly in their potency at these sites as compared to hD(2) receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522469     DOI: 10.1016/S0893-133X(01)00237-8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  13 in total

1.  Enhancing functional production of G protein-coupled receptors in Pichia pastoris to levels required for structural studies via a single expression screen.

Authors:  Nicolas André; Nadia Cherouati; Cécile Prual; Tania Steffan; Gabrielle Zeder-Lutz; Thierry Magnin; Franc Pattus; Hartmut Michel; Renaud Wagner; Christoph Reinhart
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

2.  5-HT-stimulated [35S]guanosine-5'-O-(3-thio)triphosphate binding as an assay for functional activation of G proteins coupled with 5-HT1B receptors in rat striatal membranes.

Authors:  Yuji Odagaki; Ryoichi Toyoshima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-21       Impact factor: 3.000

Review 3.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

4.  h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT.

Authors:  Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Manuelle Touzard; Mark J Millan
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

5.  F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.

Authors:  A Newman-Tancredi; M-B Assié; J-C Martel; C Cosi; L Bruins Slot; C Palmier; I Rauly-Lestienne; F Colpaert; B Vacher; D Cussac
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

6.  Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine.

Authors:  Gavin P Reynolds
Journal:  Ther Adv Psychopharmacol       Date:  2011-12

7.  Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.

Authors:  A Newman-Tancredi; J-M Rivet; D Cussac; M Touzard; C Chaput; L Marini; M J Millan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-16       Impact factor: 3.000

8.  A novel mechanism for regulating hepatic glycogen synthesis involving serotonin and cyclin-dependent kinase-5.

Authors:  Susan J Tudhope; Chung-Chi Wang; John L Petrie; Lloyd Potts; Fiona Malcomson; Julius Kieswich; Muhammad M Yaqoob; Catherine Arden; Laura J Hampson; Loranne Agius
Journal:  Diabetes       Date:  2011-11-21       Impact factor: 9.461

9.  Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Authors:  Fabio Panariello; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Schizophr Res Treatment       Date:  2010-12-06

10.  Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action.

Authors:  Patrick D Roberts; Athan Spiros; Hugo Geerts
Journal:  Alzheimers Res Ther       Date:  2012-11-26       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.